BACKGROUND: Two phase III trials have demonstrated the clinical and radiological efficacy of delayed-release dimethyl fumarate (DMF) in relapsing-remitting multiple sclerosis (RRMS). However, data on its safety and effectiveness in real-world practice are still limited. OBJECTIVES: The aim of our study was to explore the safety and tolerability profile of DMF in RRMS. We also tried to identify individual variables associated with better clinical and radiological outcomes. METHODS: We collected the clinical and magnetic resonance imaging (MRI) data of patients with RRMS who started DMF between 2012 and 2017 in seven MS clinics in central Italy. We first evaluated DMF discontinuation rates and the incidence of adverse events and side effects. We then assessed the annualized relapse rate (ARR), the number of patients with clinical relapses or disability worsening and the presence of radiological activity. Third, we investigated which baseline variables were associated with clinical and radiological outcomes. RESULTS: We collected data for 1089 patients with a mean on-treatment follow-up of 17 ± 8 months; 331 (30.4%) of these patients were treatment naïve. In total, 210 (19.5%) patients discontinued DMF mainly because of poor tolerability (n = 103) and disease activity (n = 63), and 166 (16.5%) patients presented with lymphopenia. The ARR reduced from 0.55 to 0.13. Mean change in Expanded Disability Status Scale (EDSS) score was 0.08 ± 0.44 per year. The occurrence of clinical and/or radiological activity during follow-up was associated with younger age [hazard ratio (HR) 0.97; p < 0.001], higher EDSS score (HR 1.18; p < 0.001), greater number of Gd-enhancing lesions at baseline scan (HR 1.14; p = 0.003) and prior exposure to MS treatments (HR 1.43; p = 0.02). CONCLUSION: This post-marketing data confirms the short-term safety, tolerability and effectiveness of DMF, supporting its use as an early treatment in MS.
BACKGROUND: Two phase III trials have demonstrated the clinical and radiological efficacy of delayed-release dimethyl fumarate (DMF) in relapsing-remitting multiple sclerosis (RRMS). However, data on its safety and effectiveness in real-world practice are still limited. OBJECTIVES: The aim of our study was to explore the safety and tolerability profile of DMF in RRMS. We also tried to identify individual variables associated with better clinical and radiological outcomes. METHODS: We collected the clinical and magnetic resonance imaging (MRI) data of patients with RRMS who started DMF between 2012 and 2017 in seven MS clinics in central Italy. We first evaluated DMF discontinuation rates and the incidence of adverse events and side effects. We then assessed the annualized relapse rate (ARR), the number of patients with clinical relapses or disability worsening and the presence of radiological activity. Third, we investigated which baseline variables were associated with clinical and radiological outcomes. RESULTS: We collected data for 1089 patients with a mean on-treatment follow-up of 17 ± 8 months; 331 (30.4%) of these patients were treatment naïve. In total, 210 (19.5%) patients discontinued DMF mainly because of poor tolerability (n = 103) and disease activity (n = 63), and 166 (16.5%) patients presented with lymphopenia. The ARR reduced from 0.55 to 0.13. Mean change in Expanded Disability Status Scale (EDSS) score was 0.08 ± 0.44 per year. The occurrence of clinical and/or radiological activity during follow-up was associated with younger age [hazard ratio (HR) 0.97; p < 0.001], higher EDSS score (HR 1.18; p < 0.001), greater number of Gd-enhancing lesions at baseline scan (HR 1.14; p = 0.003) and prior exposure to MS treatments (HR 1.43; p = 0.02). CONCLUSION: This post-marketing data confirms the short-term safety, tolerability and effectiveness of DMF, supporting its use as an early treatment in MS.
Authors: Jordi Río; Carlos Nos; Mar Tintoré; Nieves Téllez; Ingrid Galán; Raúl Pelayo; Manuel Comabella; Xavier Montalban Journal: Ann Neurol Date: 2006-02 Impact factor: 10.422
Authors: M Baharnoori; C T Gonzalez; A Chua; C Diaz-Cruz; B C Healy; J Stankiewicz; H L Weiner; T Chitnis Journal: Mult Scler Relat Disord Date: 2017-12-14 Impact factor: 4.339
Authors: Robbert-Jan Gieselbach; Annemarie H Muller-Hansma; Martijn T Wijburg; Marjolein S de Bruin-Weller; Bob W van Oosten; Dennis J Nieuwkamp; Frank E Coenjaerts; Mike P Wattjes; Jean-Luc Murk Journal: J Neurol Date: 2017-05-23 Impact factor: 4.849
Authors: Erin E Longbrake; Claudia Cantoni; Salim Chahin; Francesca Cignarella; Anne H Cross; Laura Piccio Journal: Mult Scler Date: 2017-05-08 Impact factor: 6.312
Authors: Ralf A Linker; De-Hyung Lee; Sarah Ryan; Anne M van Dam; Rebecca Conrad; Pradeep Bista; Weike Zeng; Xiaoping Hronowsky; Alex Buko; Sowmya Chollate; Gisa Ellrichmann; Wolfgang Brück; Kate Dawson; Susan Goelz; Stefan Wiese; Robert H Scannevin; Matvey Lukashev; Ralf Gold Journal: Brain Date: 2011-03 Impact factor: 13.501
Authors: Robert J Fox; David H Miller; J Theodore Phillips; Michael Hutchinson; Eva Havrdova; Mariko Kita; Minhua Yang; Kartik Raghupathi; Mark Novas; Marianne T Sweetser; Vissia Viglietta; Katherine T Dawson Journal: N Engl J Med Date: 2012-09-20 Impact factor: 91.245
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: L Kappos; G Giovannoni; R Gold; J T Phillips; D L Arnold; C Hotermans; A Zhang; V Viglietta; R J Fox Journal: Eur J Neurol Date: 2015-01-02 Impact factor: 6.089
Authors: Robert J Fox; Andrew Chan; Ralf Gold; J Theodore Phillips; Krzysztof Selmaj; Ih Chang; Mark Novas; Jitesh Rana; Jing L Marantz Journal: Neurol Clin Pract Date: 2016-06
Authors: Belen Pilo de la Fuente; Julia Sabín; Victoria Galán; Israel Thuissard; Susana Sainz de la Maza; Lucienne Costa-Frossard; Mayra Gómez-Moreno; Judit Díaz-Díaz; Celia Oreja-Guevara; Alberto Lozano-Ros; José M García-Domínguez; Laura Borrego; Lucía Ayuso; Andy Castro; Pedro Sánchez; Virginia Meca-Lallana; Carmen Muñoz; Ignacio Casanova; Carlos López de Silanes; Hugo Martín; Elena Rodríguez-García; Cristina Andreu-Vázquez; Rosario Blasco; Juan A García-Merino; Yolanda Aladro Journal: CNS Drugs Date: 2020-11-23 Impact factor: 5.749
Authors: Paulus S Rommer; Ron Milo; May H Han; Sammita Satyanarayan; Johann Sellner; Larissa Hauer; Zsolt Illes; Clemens Warnke; Sarah Laurent; Martin S Weber; Yinan Zhang; Olaf Stuve Journal: Front Immunol Date: 2019-07-11 Impact factor: 7.561
Authors: Robert T Naismith; Jerry S Wolinsky; Annette Wundes; Christopher LaGanke; Douglas L Arnold; Dragana Obradovic; Mark S Freedman; Mark Gudesblatt; Tjalf Ziemssen; Boris Kandinov; Ilda Bidollari; Maria Lopez-Bresnahan; Narinder Nangia; David Rezendes; Lili Yang; Hailu Chen; Shifang Liu; Jerome Hanna; Catherine Miller; Richard Leigh-Pemberton Journal: Mult Scler Date: 2019-11-04 Impact factor: 6.312
Authors: Ralf Gold; Douglas L Arnold; Amit Bar-Or; Robert J Fox; Ludwig Kappos; Oksana Mokliatchouk; Xiaotong Jiang; Jennifer Lyons; Shivani Kapadia; Catherine Miller Journal: Mult Scler Date: 2021-09-01 Impact factor: 6.312